Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

ATCC selected by ARPA-H to support next-generation BioStabilization technologies (opens in a new tab)

news-medical.net · 2026-10-29

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

16 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

The literature search

16 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 12 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 5Not checkedATCC has been selected by ARPA-H as an affiliate to provide independent verification and validation for its BioStabilization Systems (BoSS) program.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 5Not checkedBoSS is taking the '200-degree leap,' from -196 °C toward room temperature, to make life-saving cell therapies easier to store and ship.View evidenceHide evidence

As stated"200-degree leap"; from -196 °C toward room temperature

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 5Not checkedThe article says cold-chain preservation and transportation are major challenges for cell-based technologies and that reducing cold-chain dependence could lower costs, simplify distribution, and expand patient access.View evidenceHide evidence

As stated"tens of billions of dollars a year"; a single dose worth hundreds of thousands of dollars

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 5Not checkedATCC will provide working cell banks, standardized benchmarks, and independent evaluation of how well emerging stabilization technologies preserve cell quality and performance.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 5Not checkedATCC will assess each stabilization technology's reproducibility, scalability, ease of use, and overall suitability, while maintaining quality-controlled traceability.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Crossref, Europe PMC · 15 candidate papers

Explore all search results